ArticlePloS one2017
Anti-MrkA Monoclonal Antibodies Reveal Distinct Structural and Antigenic Features of MrkA.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Pre-Clinical Development of Two DNA Vaccines Encoding MrkA of Klebsiella pneumoniae: Effect of Plasmid Backbone on Immunogenicity and Protective Efficacy Against Sepsis.Microbial biotechnology · 2026Article
- Monoclonal Antibodies Targeting Bacterial Infections: A Broad Review of the Field.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Understanding the impact of Klebsiella pneumoniae K-Antigen based MAPS vaccine design on the immune response in animal models.PLoS pathogens · 2026Article
- Leveraging MrkA Display on Self-Assembling Protein Nanoparticles for Enhanced Immune Activation.ACS applied materials & interfaces · 2026Article
- The TamA protein as a subunit vaccine improves immune protection against highly virulentCurrent research in microbial sciences · 2026Article
- Biological and structural characterization of the Type 3 fimbrial subunit MrkA from Klebsiella pneumoniae.Protein science : a publication of the Protein Society · 2025Article
- Modular assembly and immunological evaluation of a promising bioconjugate nanovaccine against Klebsiella pneumoniae O2 serotype.NPJ vaccines · 2025Article
- Article
- Exploring current hypervirulentFrontiers in microbiology · 2025Review
- Article
- Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance.International journal of molecular sciences · 2024Review
- Patient-Derived Antibody Data Yields Development of Broadly Cross-Protective Monoclonal Antibody against ST258 Carbapenem-ResistantMicrobiology spectrum · 2022Article
- Anti-bacterial monoclonal antibodies: next generation therapy against superbugs.Applied microbiology and biotechnology · 2022Review
- Current Stage in the Development of Klebsiella pneumoniae Vaccines.Infectious diseases and therapy · 2021Review
- Kpi, a chaperone-usher pili system associated with the worldwide-disseminated high-risk cloneProceedings of the National Academy of Sciences of the United States of America · 2020Article
- Antibody-recruiting protein-catalyzed capture agents to combat antibiotic-resistant bacteria.Chemical science · 2020Article
- Progress towards the development of Klebsiella vaccines.Expert review of vaccines · 2019Review
- Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development.Biosensors · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antibody therapy against antibiotics resistant Klebsiella pneumoniae infections represents a promising strategy, the success of which depends critically on the ability to identify appropriate antibody targets. Using a target-agnostic strategy, we recently discovered MrkA as a potential antibody target and vaccine antigen. Interestingly, the anti-MrkA monoclonal antibodies isolated through phage display and hybridoma platforms all recognize an overlapping epitope, which opens up important questions including whether monoclonal antibodies targeting different MrkA epitopes can be generated and if they possess different protective profiles. In this study we generated four anti-MrkA antibodies targeting different epitopes through phage library panning against recombinant MrkA protein. These anti-MrkA antibodies elicited strong in vitro and in vivo protections against a multi-drug resistant Klebsiella pneumoniae strain. Furthermore, mutational and epitope analysis suggest that the two cysteine residues may play essential roles in maintaining a MrkA structure that is highly compacted and exposes limited antibody binding/neutralizing epitopes. These results suggest the need for further in-depth understandings of the structure of MrkA, the role of MrkA in the pathogenesis of Klebsiella pneumoniae and the protective mechanism adopted by anti-MrkA antibodies to fully explore the potential of MrkA as an efficient therapeutic target and vaccine antigen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.